Provided is an improved process for the preparation N-[4-[[4-(diethyl amino) phenyl](2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium inner salt sodium salt (Isosulfan blue) of formula I. It also relates to highly pure novel crystalline form of Isosulfan blue hydrate and its process for the preparation thereof. It also relates to an improved process for the preparation of Isosulfan blue sodium hydrate having not more than 0.2% of desethyl impurity of formula A.

##STR00001##

Provided is an improved process for the preparation N-[4-[[4-(diethyl amino) phenyl](2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium inner salt sodium salt (Isosulfan blue) of formula I. It also relates to highly pure novel crystalline form of Isosulfan blue hydrate and its process for the preparation thereof. It also relates to an improved process for the preparation of Isosulfan blue sodium hydrate having not more than 0.2% of desethyl impurity of formula A.

##STR00001##

The present invention provides tyrosinase-inhibiting molecules of general formula (I) and a dermopharmaceutical or cosmetic composition that includes at least one of said tyrosinase-inhibiting molecules.

##STR00001##

Provided is a method of preparing isosulfan blue.

Provided is a method of preparing isosulfan blue.

A quinone derivative with a high redox potential that does not undergo Michael addition or proto-desulfonation. This molecule addresses the key issues faced with the positive side material of an aqueous all-organic flow battery. This new molecule is 2,5-dihydroxy-4,6-dimethylbenzene-1,3-disulfonic acid (or the disulfonate salt thereof). This quinone derivative offers good solubility, electrochemical reversibility, and robustness to charge/discharge cycling. Quinones with reduced crossover are also provided.

A quinone derivative with a high redox potential that does not undergo Michael addition or proto-desulfonation. This molecule addresses the key issues faced with the positive side material of an aqueous all-organic flow battery. This new molecule is 2,5-dihydroxy-4,6-dimethylbenzene-1,3-disulfonic acid (or the disulfonate salt thereof). This quinone derivative offers good solubility, electrochemical reversibility, and robustness to charge/discharge cycling. Quinones with reduced crossover are also provided.

The present invention provides an electrolytic capacitor with excellent heat resistance, a method for manufacturing the same, a conductive composition that can constitute the electrolytic capacitor, a method for manufacturing the same, and a dopant solution and a monomer liquid for manufacturing the conductive composition. The dopant solution for a conductive polymer of the present invention comprises a dopant for a conductive polymer, the dopant dissolved in a solvent, and the dopant for the conductive polymer comprises a salt (A) of: a sulfonic acid having an anthraquinone skeleton; and one of specific alkylamine, specific alkanolamine, specific hydroxylamine and specific compound having a heterocycle having 1 to 3 nitrogen atoms in a ring thereof; and water or a lower alcohol is included as a solvent.

The present invention provides an electrolytic capacitor with excellent heat resistance, a method for manufacturing the same, a conductive composition that can constitute the electrolytic capacitor, a method for manufacturing the same, and a dopant solution and a monomer liquid for manufacturing the conductive composition. The dopant solution for a conductive polymer of the present invention comprises a dopant for a conductive polymer, the dopant dissolved in a solvent, and the dopant for the conductive polymer comprises a salt (A) of: a sulfonic acid having an anthraquinone skeleton; and one of specific alkylamine, specific alkanolamine, specific hydroxylamine and specific compound having a heterocycle having 1 to 3 nitrogen atoms in a ring thereof; and water or a lower alcohol is included as a solvent.

A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.